# Lexaria Bioscience (LEXX) — Earnings

LEXX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lexx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q3 2025 |
| Period end | May 31, 2025 |
| EPS actual | −$3.15 |
| EPS estimate | −$2.18 |
| EPS surprise | −44.83% |
| Revenue surprise | +27.01% |
| Revenue | $174,000.00 |
| Revenue estimate | $137,000.00 |
| Reported | Jul 14, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1348362/000164033425001195/lxrp_10q.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q3 2025 | Jul 14, 2025 | −$2.18 | −$3.15 | -44.83% | $137,000.00 | $174,000.00 |
| Q2 2025 | Apr 14, 2025 | −$2.45 | −$2.25 | 8.16% | $150,000.00 | $174,000.00 |
| Q1 2025 | Jan 10, 2025 | −$1.80 | −$2.40 | -33.33% | $100,000.00 | $184,000.00 |
| Q4 2024 | Nov 26, 2024 | −$1.80 | −$2.10 | -16.67% | $200,000.00 | $92,000.00 |
| Q3 2024 | Jul 12, 2024 | −$1.95 | −$1.95 | 0.00% | $106,000.00 | — |
| Q2 2024 | Apr 9, 2024 | −$1.50 | −$0.90 | 40.00% | — | $145,000.00 |
| Q1 2024 | Jan 12, 2024 | −$1.65 | −$1.95 | -18.18% | — | $151,000.00 |
| Q3 2023 | Jul 14, 2023 | −$3.75 | −$5.55 | -48.00% | $10,000.00 | $93,000.00 |
| Q2 2023 | Apr 14, 2023 | $0.00 | −$3.30 | 0.00% | — | — |
| Q1 2023 | Jan 17, 2023 | $0.00 | −$4.50 | 0.00% | — | $101,476.00 |
| Q3 2022 | Jul 14, 2022 | −$4.20 | −$6.15 | -46.43% | $120,000.00 | $100,000.00 |
| Q2 2022 | Apr 11, 2022 | −$3.15 | −$3.75 | -19.05% | $150,000.00 | $30,650.00 |
| Q1 2022 | Jan 14, 2022 | $0.00 | −$5.25 | 0.00% | — | $13,880.00 |
| Q3 2021 | Jul 15, 2021 | $0.00 | −$7.50 | 0.00% | — | $204,000.00 |

## Frequently Asked Questions

### When did Lexaria Bioscience (LEXX) last report earnings?

Lexaria Bioscience last reported on Jul 14, 2025, covering fiscal Q3 2025.

### Did LEXX beat earnings estimates?

No. Lexaria Bioscience reported EPS of −$3.15 for Q3 2025 against a −$2.18 estimate — a 44.83% miss.

### How much revenue did LEXX report last quarter?

Lexaria Bioscience reported $174,000.00 in revenue for Q3 2025, against a consensus estimate of $137,000.00.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).